Get the Stockscreener App
9.45
3.08%
-0.30
After Hours:
9.45
ARS Pharmaceuticals Inc stock is currently priced at $9.45, with a 24-hour trading volume of 400.58K.
It has seen a -3.08% decreased in the last 24 hours and a -4.26% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $9.63 pivot point. If it approaches the $9.26 support level, significant changes may occur.
Previous Close:
$9.75
Open:
$9.75
24h Volume:
400.58K
Market Cap:
$915.65M
Revenue:
-
Net Income/Loss:
$-54.37M
P/E Ratio:
-19.45
EPS:
-0.4858
Net Cash Flow:
$-59.44M
1W Performance:
+9.88%
1M Performance:
-4.26%
6M Performance:
+163.97%
1Y Performance:
+49.76%
1D Range:
$9.10
$9.80
52W Range:
$2.55
$11.27
ARS Pharmaceuticals Inc Stock (SPRY) Company Profile
Name
ARS Pharmaceuticals Inc
Sector
Industry
Phone
858 771 9307
Address
11682 El Camino Real, Suite 120, San Diego
ARS Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-31-23 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Initiated | William Blair | Outperform |
| Dec-13-22 | Initiated | SVB Leerink | Outperform |
ARS Pharmaceuticals Inc Stock (SPRY) Latest News
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
GlobeNewswire Inc.
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)
GlobeNewswire Inc.
ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's What You Should Know
Zacks Investment Research
Top 5 Health Care Stocks That May Plunge In March
Benzinga
Recent Price Trend in ARS Pharmaceuticals, Inc. (SPRY) is Your Friend, Here's Why
Zacks Investment Research
ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire Inc.
ARS Pharmaceuticals Inc Stock (SPRY) Financials Data
ARS Pharmaceuticals Inc (SPRY) Net Income 2024
SPRY net income (TTM) was -$54.37 million for the quarter ending December 31, 2023, a -56.75% decrease year-over-year.
ARS Pharmaceuticals Inc (SPRY) Cash Flow 2024
SPRY recorded a free cash flow (TTM) of -$59.44 million for the quarter ending December 31, 2023, a -47.58% decrease year-over-year.
ARS Pharmaceuticals Inc (SPRY) Earnings per Share 2024
SPRY earnings per share (TTM) was -$0.57 for the quarter ending December 31, 2023, a -54.22% decline year-over-year.
About ARS Pharmaceuticals Inc
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for patients and parents affected by severe allergic reactions. It is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for patients and their caregivers with type I allergic reactions, including food, medications, and insect bites. The company was founded in 2015 and is based in San Diego, California.
0.41%
0.14%
Cap:
|
Volume (24h):